会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Monoclonal antibody to mullerian inhibiting substance
    • 木质素抑制物质的单克隆抗体
    • US4792601A
    • 1988-12-20
    • US656482
    • 1984-10-01
    • Patricia K. DonahoeGerald P. BudzikMeredith Mudgett-Hunter
    • Patricia K. DonahoeGerald P. BudzikMeredith Mudgett-Hunter
    • C07K16/00C07K16/18C12N5/16G01N33/53A61K39/395C12N5/00C12N15/00C12P21/00
    • C12N5/163C07K16/00C07K16/18
    • In a method for preparing a monoclonal hybridoma which secretes antibodies against an immunogenic material, comprising sensitizing an appropriate source with an immunizing amount of a preparation of the immunogenic material, obtaining from the source lymphocytes having immune activity against the immunogenic material, and fusing the lymphocytes with an appropriate cell line to thereby form mixed hybridomas, the improvement wherein: the immunogenic material is present in the immunizing preparation in an amount not larger than 10% by weight, and wherein, after formation of the mixed hydridomas but prior to cloning, the method comprises the steps of: raising ascites fluid with the mixed hydridomas, then detecting immune specificity against the immunogenic material in the ascites raised fluid; and thereafter cloning the ascites raised cells which show immune specificity against the material.
    • 在制备分泌针对免疫原性物质的抗体的单克隆杂交瘤的方法中,包括用免疫量的免疫原性物质的制剂对适当的来源进行敏化,从源获得具有针对免疫原性物质的免疫活性的淋巴细胞,并融合淋巴细胞 用合适的细胞系形成混合的杂交瘤,其改进在于:免疫原性物质以不大于10重量%的量存在于免疫制剂中,并且其中,在形成混合的hydridomas之后但是在克隆之前, 方法包括以下步骤:用混合的hydridomas提升腹水,然后检测腹水引起的流体中对免疫原性物质的免疫特异性; 然后克隆显示对材料的免疫特异性的腹水升高的细胞。